| abstract |
The present disclosure provides multispecific chimeric antigen receptors (CARs) having antigenic specificity for FLT3 and CD19, FLT3 and CD22, FLT3 and CD123 or FLT3 and CD33. Nucleic acids, expression constructs, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the multispecific CARs are disclosed. Methods of treating or preventing ALL, AML and/or other forms of cancer in a mammal are also disclosed. |